Picture Berlin Partner German Biotech Days 2024 in Berlin 650x100px
Document › Details

Evolva Holding S.A.. (11/14/23). "Press Release: Evolva and Breko Broaden Partnership by Signing Agreement for the Exclusive Distribution of Veri-te Resveratrol in Germany, Austria, Thailand and Vietnam". Reinach.

Organisation Organisation Evolva Holding SA (SIX: EVE)
  Group Lallemand (Group)
Products Product resveratrol
  Product 2 dietary supplement
Person Person Rudischhauser, Doris (Dynamics Group 202208 Consultant Crisis Communication)

Evolva (SIX: EVE), a pioneer in the field of natural molecules and industrial biotech, and Breko GmbH, Bremen, Germany (“Breko”), a leading supplier of products for the food and beverage industry as well as for food supplements, functional foods and cosmetic products, have signed an agreement for the exclusive distribution of Evolva’s Veri-te™ Resveratrol for use in dietary supplements covering Germany, Austria, Thailand and Vietnam. The partners have already been working together for more than five years, resulting in compound annual revenue growth of more than 50%. With this agreement on an exclusive basis, this very successful relationship is now being formalized.

The agreement underscores the potential of Veri-te™ Resveratrol as a powerful and sustainable high-quality ingredient for use in dietary supplements as well as for use in foods in select countries. The agreement broadens the already existing long-term partnership by granting exclusivity to Breko and covering additional markets. Breko was already instrumental in obtaining approval for Veri-teTM Resveratrol from the Thai Food and Drug Administration earlier this year. Veri-te™ Resveratrol is the main pillar of Evolva’s Health Ingredients (HI) business and was a key driver for the 14% revenue growth in HI recorded in the first half of 2023.

Anne De Vos, Chief Commercial Officer of Evolva, comments: ”We have already worked with Breko in Germany and Austria since 2017 and are now very excited to deepen the close relationship with Breko by granting exclusivity and expanding into the additional markets of Thailand and Vietnam where we see also great potential. Veri-te™ Resveratrol is a responsible multi-functional ingredient with proven health benefits supported by a number of clinical studies. We expect our partner Breko to develop the business in these four countries considerably over the coming years.”

Wolfgang Loersch, Vice-President Ingredients at Breko: “We are thrilled to have been granted exclusivity for this high quality, researched and sustainable ingredient in our portfolio covering Germany, Austria, Thailand and Vietnam. We look forward to broadening the already successful partnership with Evolva.”


Doris Rudischhauser
Head of Investor Relations and Corporate Communications
+41 79 410 81 88

About Veri-te™ Resveratrol

Resveratrol is a polyphenolic compound that occurs naturally in plants such as grapes, peanuts, cranberries and other berries, albeit at low concentrations. Evolva’s Veri-te™ Resveratrol is a nature-based high-purity ingredient, made via fermentation, which ensures a stable, traceable and reliable supply. The ingredient is offered in different formats such as a cold-water dispersible or an oil and water-soluble resveratrol and is sold for use in dietary supplements, functional beverages, cosmetics, pharma applications and animal health markets.

About Evolva

Evolva is a Swiss biotech company focused on the research, development and commercialization of ingredients based on nature. We have leading businesses in Flavors and Fragrances, Health Ingredients and Health Protection. Evolva’s employees are dedicated to make the best products that can contribute to health, wellness and sustainability. Find out more at and connect with us on LinkedIn.

About Breko

Breko is one of the leading suppliers of wines, spirits, food and health ingredients. We offer a wide range of products for the food and beverage industry as well as for food supplements, functional food and cosmetics. Learn more at


This announcement is not an offer of securities into the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and may not be offered, pledged, sold, delivered or otherwise transferred, directly or indirectly, in the United States, except pursuant to an exemption from, or transaction not subject to, the registration requirements of the Securities Act. No public offering of securities is being made in the United States. Further, the securities referred to herein have not been and will not be registered under the applicable securities laws of Canada, Australia or Japan or under the applicable securities laws of any other jurisdiction where to do so might constitute a violation of such laws.

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

Record changed: 2024-01-20


Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for Lallemand (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner German Biotech Days 2024 in Berlin 650x300px

» top